ResMed Inc. (RMD) Income Statement
RMD FY2026 at a glance
Fiscal year ended June 30, 2026 · U.S. dollarsRMD revenue and net income
Where RMD's revenue goes
FY2026Each bar shows an amount and its share of revenue. RMD kept 26.9% of revenue as net income.
RMD profit margins
RMD growth rates
to FY2026| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +9.9% | +10.2% | +12.1% | +11.9% |
| Gross profit | +13.0% | +13.6% | +13.4% | +12.5% |
| Operating income | +13.2% | +19.0% | +16.1% | +16.1% |
| Net income | +8.8% | +19.3% | +26.3% | +15.8% |
| EPS (diluted) | +17.0% | +20.1% | +15.9% | +15.3% |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
RMD quarterly EPS vs estimates
ResMed beat the analyst EPS estimate in 8 of the last 8 quarters. Next report: October 29, 2026 (estimate $2.70).
RMD income statement
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.65B | $5.15B | $4.69B | $4.22B | $3.58B | $3.20B | $2.96B | $2.61B | $2.34B | $2.07B |
| Cost of revenue | $2.20B | $2.09B | $2.03B | $1.87B | $1.55B | $1.36B | $1.24B | $1.07B | $978.0M | $865.0M |
| Gross profit | $3.45B | $3.05B | $2.66B | $2.36B | $2.02B | $1.84B | $1.72B | $1.54B | $1.36B | $1.20B |
| Research & development | $378.3M | $331.3M | $307.5M | $287.6M | $253.6M | $225.3M | $201.9M | $180.7M | $155.1M | $144.5M |
| Sales, general & admin | $1.12B | $991.0M | $917.1M | $874.0M | $739.4M | $670.4M | $676.7M | $645.0M | $600.4M | $559.4M |
| Total operating expenses | $1.54B | $1.37B | $1.34B | $1.22B | $1.02B | $935.4M | $908.7M | $957.3M | $820.3M | $775.9M |
| Operating income | $1.91B | $1.69B | $1.32B | $1.13B | $1.00B | $903.7M | $809.7M | $579.3M | $541.8M | $425.8M |
| Interest income | — | $2.5M | $51.6M | $44.7M | $43.0M | $34.8M | $63.1M | $2.3M | $16.4M | $17.1M |
| Interest expense | $29.0M | $12.6M | $45.7M | $47.4M | $22.3M | $24.0M | $40.4M | $36.2M | $28.4M | $28.2M |
| Income before taxes | $1.92B | $1.68B | $1.26B | $1.10B | $960.5M | $883.7M | $733.1M | $518.8M | $521.3M | $418.7M |
| Income taxes | $396.1M | $276.8M | $243.8M | $204.1M | $181.0M | $409.2M | $111.4M | $114.3M | $205.7M | $76.5M |
| Net income | $1.52B | $1.40B | $1.02B | $897.6M | $779.4M | $474.5M | $621.7M | $404.6M | $315.6M | $342.3M |
| EBITDA | $2.15B | $1.91B | $1.53B | $1.36B | $1.18B | $1.10B | $990.4M | $705.8M | $680.2M | $568.9M |
| EPS (diluted) | $11.17 | $9.55 | $7.73 | $6.45 | $5.79 | $5.33 | $4.76 | $3.65 | $3.53 | $2.83 |
| Gross margin | 61.1% | 59.4% | 56.7% | 55.8% | 56.6% | 57.5% | 58.1% | 59.0% | 58.2% | 58.1% |
| Operating margin | 33.8% | 32.7% | 28.2% | 26.8% | 28.0% | 28.3% | 27.4% | 22.2% | 23.2% | 20.6% |
| Net margin | 26.9% | 27.2% | 21.8% | 21.3% | 21.8% | 14.8% | 21.0% | 15.5% | 13.5% | 16.6% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.46B | $1.43B | $1.42B | $1.34B | $1.35B | $1.29B | $1.28B | $1.22B | $1.22B | $1.20B | $1.16B | $1.10B |
| Cost of revenue | $602.4M | $540.4M | $538.1M | $514.8M | $527.9M | $525.3M | $530.8M | $507.3M | $518.9M | $515.4M | $493.4M | $502.3M |
| Gross profit | $861.2M | $891.0M | $884.7M | $820.8M | $820.1M | $766.4M | $751.3M | $717.2M | $704.3M | $681.6M | $669.4M | $600.1M |
| Research & development | $105.7M | $94.3M | $91.0M | $87.3M | $86.4M | $83.9M | $81.4M | $79.5M | $80.9M | $77.1M | $73.9M | $75.7M |
| Sales, general & admin | $296.3M | $285.7M | $278.4M | $259.2M | $265.1M | $245.3M | $241.6M | $239.0M | $242.2M | $229.9M | $222.2M | $222.9M |
| Total operating expenses | $412.5M | $391.2M | $387.1M | $374.3M | $365.5M | $340.1M | $334.0M | $329.9M | $323.0M | $307.0M | $394.3M | $311.1M |
| Operating income | $448.7M | $499.8M | $497.6M | $446.5M | $454.5M | $426.3M | $417.2M | $387.3M | $381.2M | $374.6M | $275.1M | $289.0M |
| Interest income | — | — | $9.8M | $4.1M | $4.5M | $4.5M | $1.1M | $1.4M | — | — | — | $19.5M |
| Interest expense | $20.9M | $12.3M | $7.9M | $8.8M | $5.8M | $3.2M | $4.8M | $5.5M | $9.6M | $14.4M | $13.8M | $15.0M |
| Income before taxes | $474.2M | $502.3M | $496.1M | $446.8M | $458.1M | $417.7M | $418.3M | $383.5M | $357.7M | $375.4M | $259.5M | $272.2M |
| Income taxes | $90.7M | $103.6M | $103.6M | $98.3M | $78.3M | $52.7M | $73.7M | $72.1M | $65.5M | $74.9M | $50.7M | $52.8M |
| Net income | $383.4M | $398.7M | $392.6M | $348.5M | $379.7M | $365.0M | $344.6M | $311.4M | $292.2M | $300.5M | $208.8M | $219.4M |
| EBITDA | $503.8M | $583.6M | $566.4M | $513.3M | $532.3M | $469.6M | $479.0M | $442.7M | $362.4M | $444.4M | $392.7M | $340.6M |
| EPS (diluted) | $2.95 | $2.86 | $2.81 | $2.55 | $2.55 | $2.37 | $2.43 | $2.20 | $2.08 | $2.13 | $1.88 | $1.64 |
| Gross margin | 58.8% | 62.2% | 62.2% | 61.5% | 60.8% | 59.3% | 58.6% | 58.6% | 57.6% | 56.9% | 57.6% | 54.4% |
| Operating margin | 30.7% | 34.9% | 35.0% | 33.4% | 33.7% | 33.0% | 32.5% | 31.6% | 31.2% | 31.3% | 23.7% | 26.2% |
| Net margin | 26.2% | 27.9% | 27.6% | 26.1% | 28.2% | 28.3% | 26.9% | 25.4% | 23.9% | 25.1% | 18.0% | 19.9% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in RMD's financial statements (latest annual report filed August 13, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
RMD financial results
In fiscal year 2026 (ended June 30, 2026), ResMed reported revenue of $5.7 billion, up 9.9% from the year before. It had net income of $1.5 billion (up 8.8%), a net profit margin of 26.9%. Diluted earnings per share came to $11.17. Over five years revenue grew at an average rate of 12.1% a year.
See the RMD stock overview for the latest quote and news, or the RMD chart for price history and technical indicators.
RMD income statement FAQ
What is ResMed's annual revenue?
ResMed reported total revenue of $5.7 billion for fiscal year 2026, which ended on June 30, 2026. That was up 9.9% from $5.1 billion the previous year.
Is ResMed profitable?
Yes. ResMed reported net income of $1.5 billion in fiscal 2026, a net profit margin of 26.9%; its operating margin was 33.8%.
What is ResMed's gross margin?
ResMed's gross margin was 61.1% in fiscal 2026: for every $100 of revenue, ResMed kept $61 after the direct cost of its products and services.
How much does ResMed spend on research and development?
ResMed spent $378.3 million on research and development in fiscal 2026, 6.7% of revenue.
How fast is ResMed growing?
Revenue grew 12.1% a year on average over the last five fiscal years, from $3.2 billion to $5.7 billion.
What are ResMed's earnings per share?
ResMed earned $11.17 per diluted share in fiscal 2026, compared with $9.55 a year earlier.
When will ResMed report its next earnings?
ResMed is expected to report results for the quarter ending September 30, 2026 on October 29, 2026 after the market closes.
When does ResMed's fiscal year end?
ResMed's fiscal year ends in June. The latest annual report covers the year ended June 30, 2026 and was filed on August 13, 2026.